Thibaud Damy

Cardiologue

Enseignants chercheurs

Publications

2024

Tamisier R, Damy T, Bailly S, Goutorbe F, Davy J-M, Lavergne F, Palot A, Verbraecken JA, d'Ortho M-P, Pépin J-L, d'Ortho M-P, Pépin J-L, Davy J-M, Damy T, Tamisier R. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024;113:412-421.
Tamisier R, Damy T, Bailly S, Goutorbe F, Davy J-M, Lavergne F, Palot A, Verbraecken JA, d'Ortho M-P, Pépin J-L, d'Ortho M-P, Pépin J-L, Davy J-M, Damy T, Tamisier R. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024;113:412-421.
Broussier A, Paugam M, Liu N, Oghina S, Kharoubi M, Lafont C, Zaroui A, Galat A, Hittinger L, Teiger E, David JPhilippe, Bastuji-Garin S, Damy T. Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis. ESC Heart Fail. 2024.

2023

Berthelot E, Broussier A, Hittinger L, Donadio C, Rovani X, Salengro E, Megbemado R, Godreuil C, Belmin J, David JPhilippe, Genet B, Damy T. Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure. ESC Heart Fail. 2023;10(3):2042-2050.
Dang J, Segaux L, Moktefi A, Stehlé T, Kharoubi M, Karoui KEl, Remy P, Grimbert P, Planté-Bordeneuve V, Guendouz S, Galat A, Mallet S, Oghina S, Chadha GDeep Singh, Zaroui A, Fanen P, Canoui-Poitrine F, Damy T, Audard V. Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid. 2023;30(1):38-48.
Damy T. [The taboo of the impact of end of life and death on caregivers]. Soins. 2023;68(874):18-24.
Bezard M, Kharoubi M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Moktefi A, Abulizi M, Deux J-F, Lemonnier F, Guendouz S, Chalard C, Zaroui A, Itti E, Hittinger L, Teiger E, Oghina S, Damy T. Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. Mayo Clin Proc. 2023;98(1):48-59.
Dang J, Ferlicot S, Misrahi M, Mussini C, Kounis I, Remy P, Samuel D, Planté-Bordeneuve V, Adams D, Funalot B, Snanoudj R, Damy T, Moktefi A, Audard V, Zaidan M. Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study. Nephrol Dial Transplant. 2023;38(9):2019-2030.
Fauvel C, Bonnet G, Mullens W, Giraldo CInes Salda, Mežnar AZupan, Barasa A, Tokmakova M, Shchendrygina A, Costa FMoscoso, Mapelli M, Zemrak F, Tops LF, Jakus N, Sultan A, Bahouth F, Hadjseyd C-E, Salvat M, Anselmino M, Messroghli D, Weberndörfer V, Giverts I, Bochaton T, Courand PYves, Berthelot E, Legallois D, Beauvais F, Bauer F, Lamblin N, Damy T, Girerd N, Sebbag L, Pezel T, Cohen-Solal A, Rosano G, Roubille F, Mewton N. Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey. Eur J Heart Fail. 2023;25(2):213-222.
Kharoubi M, Bezard M, Broussier A, Galat A, Gounot R, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Itti E, Lemonnier F, Chadha GDeep Sing, Guendouz S, Mallet S, Zaroui A, Audard V, Audureau E, Le Corvoisier P, Hittinger L, Bordeneuve VPlanté, Lefaucheur J-P, Amiot A, Béquignon E, Bartier S, Leroy V, Teiger E, Oghina S, Damy T. Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovasc Med. 2023;10:1124660.
Logeart D, Damy T, Doublet M, Salvat M, Tribouilloy C, Bauer F, Eicher J-C, Picard F, Roul G, Trochu J-N, De Groote P, Bihry N, Berthelot E, Jondeau G, Seronde M-F, Roubille F, Isnard R. Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers. Arch Cardiovasc Dis. 2023;116(1):18-24.
Lund LH, Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Kalus S, Ferber PC, Koch C, Maggioni AP. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry. Int J Cardiol. 2023;370:279-286.
Secretan P-H, Vieillard V, Thirion O, Annereau M, Yayé HSadou, Astier A, Paul M, Damy T, Do B. 3D-Printed, Liquid-Filled Capsules of Concentrated and Stabilized Polyphenol Epigallocatechin Gallate, Developed in a Clinical Trial. Antioxidants (Basel). 2023;12(2).
Damy T, Bourel G, Slama M, Algalarrondo V, Lairez O, Fournier P, Costa J, Pelcot F, Farrugia A, Zaleski IDurand, Lilliu H, Rault C, Bartoli M, Fievez S, Granghaud A, Rudant J, Coste A, Cosson CNoirot, Squara P-A, Narbeburu M, De Neuville B, Charron P. Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases. Orphanet J Rare Dis. 2023;18(1):345.
Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHWilson, Yu W-C, Obici L, Simões M, Fernandes F, Poulsen SHvitfeldt, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023;389(17):1553-1565.
Mohty D, Omer MH, Ahmad O, Alayary I, Alzahrani T, Damy T, Fadel B. Transthyretin cardiac amyloidosis in Saudi Arabia and the Middle East: insights, projected prevalence and practical applications. Front Cardiovasc Med. 2023;10:1265681.
Wardhere A, Bampatsias D, Fine N, García-Pavía P, Grogan M, Kristen AV, Damy T, Sekijima Y, Maurer MS. Heterogeneous worldwide access and pricing of Tafamidis. Amyloid. 2023:1-3.
Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, Keohane D, Wang R, Ines M, Kumar N, Munteanu C, Cappelli F. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023;10:1238843.
Damy T, Zaroui A, de Tournemire M, Kharoubi M, Gounot R, Galat A, Guendouz S, Funalot B, Itti E, Roulin L, Audard V, Fanen P, Leroy V, Poulot E, Belhadj K, Mallet S, Chadah GDeep Singh, Planté-Bordeneuve V, Gendre T, Chevalier X, Guignard S, Béquignon E, Bartier S, Folliguet T, Lemonier F, Audureau E, Tixier D, Canoui-Poitrine F, Lefaucheur J-P, Souvannanorath S, Authier F-J, Maupou S, Hittinger L, Molinier-Frenkel V, David J-P, Broussier A, Oghina S, Teiger E. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. Arch Cardiovasc Dis. 2023;116(10):433-446.
Nicol M, Vergaro G, Damy T, Kharoubi M, Baudet M, Canuti ESofia, Aimo A, Castiglione V, Emdin M, Royer B, Harel S, Cohen-Solal A, Arnulf B, Logeart D. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study. Front Cardiovasc Med. 2023;10:1179968.
Albenque G, Bezard M, Kharoubi M, Odouard S, Lunati A, Poullot E, Zaroui A, Teiger E, Hittinger L, Audard V, Karoui KEl, Funalot B, Fanen P, Damy T, Oghina S. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study. Amyloid. 2023;30(4):407-415.
García-Pavía P, Siepen FAus dem, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023;389(3):239-250.
Delbarre M-A, Girardon F, Roquette L, Blanc-Durand P, Hubaut M-A, Hachulla E, Semah F, Huglo D, Garcelon N, Marchal E, Esper IEl, Tribouilloy C, Lamblin N, Duhaut P, Schmidt J, Itti E, Damy T. Deep Learning on Bone Scintigraphy to Detect Abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2023;16(8):1085-1095.

2022

Damy T, Zaroui A, Oghina S. The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response. Eur Heart J. 2022;43(45):4736-4738.
Guendouz S, Grimbert P, Radu C, Cherqui D, Salloum C, Mongardon N, Maghrebi S, Belhadj K, Le Bras F, Teiger E, Couetil J-P, Balan A, Kharoubi M, Bezard M, Oghina S, Bodez D, Hittinger L, Audard V, Planté-Bordeneuve V, de la Taille A, Bergoend E, Frenkel V, Fanen P, Leroy V, Duvoux C, Carmagnat M, Folliguet T, Damy T. Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis. Transplant Direct. 2022;8(7):e1323.
Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiol. 2022;18(3):165-172.
Girerd N, Mewton N, Tartiere J-M, Guijarro D, Jourdain P, Damy T, Lamblin N, Bayes-Génis A, Pellicori P, Januzzi JL, Rossignol P, Roubille F. Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail. 2022;24(5):750-761.
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Radiopharmaceutical supply disruptions and the use of Tc-hydroxymethylene diphosphonate as an alternative to Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. J Nucl Cardiol. 2022;29(5):2748-2760.
C Quarta C, Fontana M, Damy T, Catini J, Simoneau D, Mercuri M, García-Pavía P, Maurer MS, Palladini G. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy. Front Cardiovasc Med. 2022;9:1073503.
Damy T, Benedyga V, Pezel T, Berthelot E, Gauthier J, Habib G, Iliou M-C, Aupetit J-F, Baudry G, De Groote P, Logeart D, Chaufourier L, Ciobotaru V, Pousset F, Beauvais F, Bauer F, Zores F, Lairez O, Richard K, Hittinger L, Teiger E, Taieb C, Audureau E. Prescription, Compliance, and Burden Associated with Salt-Restricted Diets in Heart Failure Patients: Results from the French National OFICSel Observatory. Nutrients. 2022;14(2).
Abroud H, Beldi-Ferchiou A, Audard V, Lemonnier F, Le Bras F, Belhadj K, Moktefi A, Poullot E, Karoui KEl, Dupuis J, Maarek A, Roulin L, Delfau-Larue M-H, Oghina S, Kharoubi M, Bezard M, Zaroui A, Damy T, Molinier-Frenkel V. Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis. EJHaem. 2022;3(3):828-837.
Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, Lavatelli F, Picken MM, Röcken C, Schönland S, Ueda M, Westermark P. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid. 2022;29(1):8-13.
Colombat M, Gaspard M, Camus M, Dalloux-Chioccioli J, Delas A, Poullot E, Moktefi A, François A, Moreau A, Gibier J-B, Raynaud P, Huart A, Piedrafita A, Gilhodes J, Lairez O, Grateau G, Georgin-Lavialle S, Maisonneuve H, Moreau P, Jaccard A, Bridoux F, Planté-Bordeneuve V, Damy T, Mal H, Brousset P, Valleix S, Burlet-Schiltz O. Mass spectrometry-based proteomics in clinical practice amyloid typing: state-of-the-art from a French nationwide cohort. Haematologica. 2022;107(12):2983-2987.
Damy T, Adams D, Bridoux F, Grateau G, Planté-Bordeneuve V, Ghiron Y, Farrugia A, Pelcot F, Taieb C, Labeyrie C, Jaccard A, Georgin-Lavialle S. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29(3):165-174.
Fischer K, Lellouche N, Damy T, Martins R, Clementy N, Bisson A, Lesaffre F, Espinosa M, Garcia R, Degand B, Serzian G, Jourda F, Huttin O, Guichard J-B, Devilliers H, Eicher J-C, Laurent G, Guenancia C. Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis. ESC Heart Fail. 2022;9(1):740-750.
Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, AbouEzzeddine OF, Mussinelli R, Gagliardi C, Kharoubi M, Griffin JM, Dispenzieri A, Vilches S, Perlini S, Longhi S, Oghina S, Rivas A, Grogan M, Maurer MS, Damy T, Palladini G, Rapezzi C, García-Pavía P. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. JACC CardioOncol. 2022;4(4):442-454.
Hourqueig M, Bouzille G, Mirabel M, Huttin O, Damy T, Labombarda F, Eicher J-C, Charron P, Habib G, Réant P, Hagège A, Donal E. Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY). Clin Res Cardiol. 2022;111(2):163-174.
Jobbé-Duval A, Bezard M, Moutereau S, Kharoubi M, Oghina S, Zaroui A, Galat A, Chalard C, Hugon-Vallet E, Lemonnier F, Eyharts D, Poulot E, Fanen P, Funalot B, Molinier-Frenkel V, Audard V, Hittinger L, Delbarre MAntoine, Teiger E, Damy T. Prevalence and determinants of iron deficiency in cardiac amyloidosis. ESC Heart Fail. 2022;9(2):1314-1327.
Kharoubi M, Bodez D, Bezard M, Zaroui A, Galat A, Guendouz S, Gendre T, Hittinger L, Attias D, Mohty D, Bergoend E, Itti E, Lebras F, Hamon D, Poullot E, Molinier-Frenkel V, Lellouche N, Deux J-F, Funalot B, Fannen P, Oghina S, Arrouasse R, Lecorvoisier P, Souvannanorath S, Amiot A, Teiger E, Bougouin W, Damy T. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid. 2022;29(2):79-91.
Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran S, Ogunbiyi O, Kharoubi M, Ganeshananthan S, Ganeshananthan S, Gilbertson JA, Rowczenio D, Wechalekar A, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Damy T, Fontana M, Gillmore JD. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022;43(27):2622-2632.
Maggioni AP, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Lund LH, Kalus S, Ferber PC, Hussain RI, Koch C, Zeymer U. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry. ESC Heart Fail. 2022;9(6):4209-4218.
Moulin T, Hamon D, Djouadi K, d'Humières T, Elbaz N, Boukantar M, Zerbib C, Rouffiac S, Dhanjal TS, Ernande L, Derumeaux G, Teiger E, Damy T, Lellouche N. Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real-world experience. ESC Heart Fail. 2022;9(5):3101-3112.
Pasteur-Rousseau A, Odouard S, Souibri K, Sebag FA, Deux J-F, Damy T. [Cardiac imaging in infiltrative cardiomyopathies. What cardiovascular imaging modalities to propose in hypertrophic cardiomyopathies ?]. Ann Cardiol Angeiol (Paris). 2022;71(2):63-74.
Touboul O, Algalarrondo V, Oghina S, Elbaz N, Rouffiac S, Hamon D, Extramiana F, Gandjbakhch E, d'Humières T, Marijon E, Dhanjal TS, Teiger E, Damy T, Lellouche N. Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants. ESC Heart Fail. 2022;9(5):3556-3564.
Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Lund LH, Kalus S, Ferber PC, Hussain RI, Koch C, Maggioni AP. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):469-477.
Odouard S, Abulizi M, Kharoubi M, Oghina S, Guendouz S, Zaroui A, Teiger E, Itti E, Damy T, Galat A. Tafamidis Decreases Cardiac Uptake of Tc-HMDP in Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15(12):2149-2151.

2021

Pezel T, Berthelot E, Gauthier J, Chong-Nguyen C, Iliou MC, Juillière Y, Galinier MC, De Groote P, Beauvais F, Bauer F, Vergeylen U, Gellen B, Raphael P, Bezard M, Ricci J-E, Boiteux M-C, Bonnefous L, Bodez D, Audureau E, Damy T. Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the OFICSel study). Arch Cardiovasc Dis. 2021;114(1):51-58.
Bezard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Gendre T, Audard V, Karoui KEl, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Planté-Bordeneuve V, Oghina S, Damy T. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail. 2021;23(2):264-274.
Berthelot E, Broussier A, Damy T, Donadio C, Cosson S, Rovani X, Salengro E, Billebeau G, Megbemado R, Rekik N, Godreuil C, Richard K, Shourick J, Assayag P, Belmin J, David JPhilippe, Hittinger L. Good performance in the management of acute heart failure in cardiogeriatric departments: the ICREX-94 experience. BMC Geriatr. 2021;21(1):288.
Kharoubi M, Roche F, Bezard M, Hupin D, Silva S, Oghina S, Chalard C, Zaroui A, Galat A, Guendouz S, Canoui-Poitrine F, Hittinger L, Teiger E, Lefaucheur J-P, Damy T. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. ESC Heart Fail. 2021;8(2):1656-1665.
Broussier A, David JPhilippe, Kharoubi M, Oghina S, Segaux L, Teiger E, Laurent M, Fromantin I, Bastuji-Garin S, Damy T. Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg. J Clin Med. 2021;10(15).
d'Humières T, Savale L, Inamo J, Deux J-F, Deswarte S, Lionnet F, Loko G, Chantalat C, Damy T, Guillet H, d'Orengiani ALaure Pham, Galactéros F, Audureau E, Maitre B, Humbert M, Derumeaux G, Bartolucci P. Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. Am J Hematol. 2021;96(9):1166-1175.
Deux J-F, Nouri R, Tacher V, Zaroui A, Derbel H, Sifaoui I, Chevance V, Ridouani F, Galat A, Kharoubi M, Oghina S, Guendouz S, Audureau E, Teiger E, Kobeiter H, Damy T. Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. Radiology. 2021;300(2):326-335.
Pezel T, Audureau E, Mansourati J, Baudry G, Ben Driss A, Durup F, Fertin M, Godreuil C, Jeanneteau J, Kloeckner M, Koukoui F, Kesri-Tartière L, Laperche T, Roubille F, Cohen-Solal A, Damy T. Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Fail. 2021;8(2):1509-1521.
Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98-105.
Adam RDaniel, Coriu D, Jercan A, Bădeliţă S, Popescu BA, Damy T, Jurcuţ R. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021;8(4):2380-2396.
Damy T, Chouihed T, Delarche N, Berrut G, Cacoub P, Henry P, Lamblin N, Andrès E, Hanon O. Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper. J Clin Med. 2021;10(16).
Damy T, Conceição I, García-Pavía P, Gillmore J, Jandhyala R, Sabbat J, Wixner J, Coelho T. A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid. 2021;28(3):189-198.
García-Pavía P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, Nativi-Nicolau J, Obici L, Rapezzi C, Sekijima Y, Elliott PM. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895-905.
Girerd N, Chapet N, Roubille C, Roncalli J, Salvat M, Mouquet F, Lamblin N, Gueffet J-P, Damy T, Galinier M, Tartiere J-M, Janssen C, Berthelot E, Aguilhon S, Escamilla R, Roubille F. Vaccination for Respiratory Infections in Patients with Heart Failure. J Clin Med. 2021;10(19).
Oghina S, Bougouin W, Bezard M, Kharoubi M, Komajda M, Cohen-Solal A, Mebazaa A, Damy T, Bodez D. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC Heart Fail. 2021;9(3):169-178.
Bonnefous L, Kharoubi M, Bezard M, Oghina S, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Deux J-F, Audard V, Itti E, Damy T, Audureau E. Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis. J Am Coll Cardiol. 2021;78(22):2177-2192.
Abulizi M, Sifaoui I, Wuliya-Gariepy M, Kharoubi M, Israël J-M, Emsen B, Bodez D, Monnet A, Didierlaurent D, Tacher V, Luciani A, Damy T, Deux J-F, Itti E. F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2021;28(4):1586-1595.
Beauvais F, Tartière L, Pezel T, Motet C, Aumont M-C, Baudry G, Eicher J-C, Galinier M, Gellen B, Guihaire J, Legallois D, Lequeux B, Mika D, Mouquet F, Salvat M, Taieb C, Zores F, Berthelot E, Damy T. First symptoms and health care pathways in hospitalized patients with acute heart failure: ICPS2 survey. A report from the Heart Failure Working Group (GICC) of the French Society of Cardiology. Clin Cardiol. 2021;44(8):1144-1150.
Berthelot E, Flécher E, Roubille F, Damy T, Lamblin N. [Impact de la pandémie de COVID-19 sur la charge des patients atteints d'insuffisance cardiaque chronique en France]. Ann Cardiol Angeiol (Paris). 2021;70(4):191-195.
Bezard M, Oghina S, Vitiello D, Kharoubi M, Kordeli E, Galat A, Zaroui A, Guendouz S, Gilles F, Shourick J, Hamon D, Audard V, Teiger E, Poullot E, Molinier-Frenkel V, Lemonnier F, Agbulut O, Le Bras F, Damy T. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS One. 2021;16(9):e0257189.
Brannagan TH, Auer-Grumbach M, Berk JL, Briani C, Bril V, Coelho T, Damy T, Dispenzieri A, Drachman BM, Fine N, Gaggin HK, Gertz M, Gillmore JD, Gonzalez E, Hanna M, Hurwitz DR, Khella SL, Maurer MS, Nativi-Nicolau J, Olugemo K, Quintana LF, Rosen AM, Schmidt HH, Shehata J, Waddington-Cruz M, Whelan C, Ruberg FL. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis. 2021;16(1):204.
Damy T, García-Pavía P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277-285.
Kharoubi M, Bezard M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Lemonnier F, Guendouz S, Chalard C, Zaroui A, Audard V, Béquignon E, Bodez D, Itti E, Hittinger L, Audureau E, Teiger E, Oghina S, Damy T. History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Fail. 2021;8(6):5501-5512.
Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, Suhr OB, Saraiva MJ, Hock C, Nitsch RM. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142.
Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, Inamo J, Montfort A, Neviere R, Damy T, Harel S, Royer B, Baudet M, Cohen-Solal A, Arnulf B, Logeart D. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail. 2021;23(2):231-239.
Oghina S, Bougouin W, Kharoubi M, Bonnefous L, Galat A, Guendouz S, Bezard M, Le Bras F, Deux J-F, Itti E, Moktefi A, Fanen P, Teiger E, Mohty D, Damy T, Bodez D. Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation. J Clin Med. 2021;10(21).
Oghina S, Josse C, Bezard M, Kharoubi M, Delbarre M-A, Eyharts D, Zaroui A, Guendouz S, Galat A, Hittinger L, Fanen P, Teiger E, Mouri N, Montestruc F, Damy T. Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. J Clin Med. 2021;10(21).
Poullot E, Oghina S, Kalsoum S, Damy T. [Cardiac amyloidosis]. Ann Pathol. 2021;41(1):25-37.
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021;9(2):115-123.
Roncalli J, Roubille F, Lamblin N, Girerd N, Mouquet F, Chapet N, Roubille C, Berthelot E, Galois K, Battistella P, Jondeau G, Tartiere J-M, Aguilhon S, Gueffet J-P, Salvat M, Damy T, Galinier M. Coronavirus disease vaccination in heart failure: No time to waste. Arch Cardiovasc Dis. 2021;114(5):434-438.
Secretan P-H, Thirion O, Yayé HSadou, Damy T, Astier A, Paul M, Do B. Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations. Pharmaceuticals (Basel). 2021;14(12).
Damy T, Sultan MB, Witteles R. Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'. Eur J Heart Fail. 2021;23(6):1057-1058.
Gounot R, Le Bras F, Dupuis J, Oghina S, Bodez D, Roulin L, Maarek A, Ladaique A, Beldi-Ferchiou A, Poullot E, Molinier-Frenkel V, Haioun C, Damy T, Belhadj K, Lemonnier F. Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment. Leuk Lymphoma. 2021;62(4):979-983.
Pasquer H, Belhadj K, Dupuis J, Oghina S, Galat A, Ladaique A, Maarek A, Roulin L, Gounot R, Poulot E, Beldi-Ferchiou A, Molinier-Frenkel V, Haioun C, Damy T, Le Bras F, Lemonnier F. Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis. Br J Haematol. 2021;193(3):674-677.
Moulin T, Landes R, Ouazana V, Abehsira G, Lim P, Huguet R, Damy T, Teiger E, Lellouche N, Hamon D. Severe Heart Failure Associated With Tachycardia-Induced Cardiomyopathy Due to Incessant Atrioventricular Re-Entrant Tachycardia. JACC Case Rep. 2021;3(3):479-483.

2020

Mohty D, Pibarot P, Damy T. Aortic stenosis and amyloid heart disease: 'the 2A dangerous liaisons'. Eur Heart J. 2020;41(29):2815.
Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS. DISCOVERY: prevalence of transthyretin () mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid. 2020;27(4):223-230.
Berthelot E, Jourdain P, Bailly MTam, Bouchachi A, Gellen B, Rouquette A, Damy T, Hervé P, Chemla D, Assayag P. Echocardiographic Evaluation of Left Ventricular Filling Pressure in Patients With Heart Failure With Preserved Ejection Fraction: Usefulness of Inferior Vena Cava Measurements and 2016 EACVI/ASE Recommendations. J Card Fail. 2020;26(6):507-514.
Malka N, Abulizi M, Kharoubi M, Oghina S, Galat A, Le Bras F, Moktefi A, Guendouz S, Molinier-Frenkel V, Fanen P, Funalot B, Lefaucheur J-P, Blanc-Durand P, Deux J-F, Audard V, Bodez D, Itti E, Damy T. Extracardiac soft tissue uptake, evidenced on early Tc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. Eur J Nucl Med Mol Imaging. 2020;47(10):2396-2406.
Tamisier R, Damy T, Davy J-M, Verbraecken JA, Bailly S, Lavergne F, Palot A, Goutorbe F, Pépin J-L, d'Ortho M-P. Cohort profile: FACE, prospective follow-up of chronic heart failure patients with sleep-disordered breathing indicated for adaptive servo ventilation. BMJ Open. 2020;10(7):e038403.
Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Lund LH, Di Comite G, Hupfer S, Maggioni AP. Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Fail. 2020;7(2):727-736.
Aouate D, Menet A, Bellevre D, Damy T, Marechaux S. Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy. Eur Heart J Case Rep. 2020;4(3):1-5.

2019

Bartier S, Bodez D, Kharoubi M, Guellich A, Canoui-Poitrine F, Chatelin V, Coste A, Damy T, Béquignon E. Association between hearing loss and hereditary ATTR amyloidosis. Amyloid. 2019;26(4):234-242.
Bartier S, Bodez D, Kharoubi M, Canoui-Poitrine F, Chatelin V, Henrion C, Coste A, Damy T, Béquignon E. Pharyngo-laryngeal involvement in systemic amyloidosis with cardiac involvement: a prospective observational study. Amyloid. 2019;26(4):216-224.
Flécher E, Guihaire J, Pozzi M, Ouattara A, Baudry G, Berthelot E, Beauvais F, Radu C, Dorent R, Sebbag L, Galli E, Roubille F, Damy T, Verhoye JPhilippe, Leprince P, Obadia J-F, Lebreton G. Extracorporeal membrane oxygenation support in acute circulatory failure: A plea for regulation and better organization. Arch Cardiovasc Dis. 2019;112(6-7):441-449.
Hagège A, Réant P, Habib G, Damy T, Barone-Rochette G, Soulat G, Donal E, Germain DP. Fabry disease in cardiology practice: Literature review and expert point of view. Arch Cardiovasc Dis. 2019;112(4):278-287.
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Quarta CCristina, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, Gallet R, Teiger E, Côté N, Clavel M-A, Tournoux F, Pibarot P, Damy T. Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(21):2638-2651.
Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, García-Pavía P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709-716.
Cholet C, Damy T, Legou F, Kobeiter H, Rahmouni A, Deux J-F. Quantification of Myocardial Enhancement on Cine-MRI: Diagnostic Value in Cardiac Amyloidosis. Acad Radiol. 2019;26(6):e98-e107.
Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M, Sadeh M, Sarafov S, Tournev I, Ueda M. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3-9.
Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu C-R, Ong M-L, Coelho T, Rapezzi C. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2019;43(5):391-400.
Dang J, Abulizi M, Moktefi A, Karoui KEl, Deux J-F, Bodez D, Le Bras F, Belhadj K, Remy P, Issaurat P, Planté-Bordeneuve V, Molinier-Frenkel V, Fanen P, Guendouz S, Kharoubi M, Itti E, Damy T, Audard V. Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. Mayo Clin Proc. 2019;94(6):961-975.
Galat A, Guellich A, Bodez D, Lipskaia L, Moutereau S, Bergoend E, Hue S, Ternacle J, Mohty D, Monin J-L, Derumeaux G, Radu C, Damy T. Causes and consequences of cardiac fibrosis in patients referred for surgical aortic valve replacement. ESC Heart Fail. 2019;6(4):649-657.
Mirabel M, Damy T, Donal E, Huttin O, Labombarda F, Eicher J-C, Cervino C, Laurito M, Offredo L, Tafflet M, Jouven X, Giura G, Desnos M, Jeunemaître X, Empana J-P, Charron P, Habib G, Réant P, Hagège A. Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: A study from the French register of hypertrophic cardiomyopathy (REMY). Int J Cardiol. 2019;275:107-113.
Pradel S, Magne J, Jaccard A, Fadel BM, Boulogne C, Salemi VMaria Cury, Damy T, Aboyans V, Mohty D. Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study. Int J Cardiovasc Imaging. 2019;35(5):845-854.
Richard P, Ader F, Roux M, Donal E, Eicher J-C, Aoutil N, Huttin O, Selton-Suty C, Coisne D, Jondeau G, Damy T, Mansencal N, Casalta A-C, Michel N, Haentjens J, Faivre L, Lavoute C, Nguyen K, Tregouët D-A, Habib G, Charron P. Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity. Clin Genet. 2019;95(3):356-367.
Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019;139(4):431-443.
Villemain O, Correia M, Mousseaux E, Baranger J, Zarka S, Podetti I, Soulat G, Damy T, Hagège A, Tanter M, Pernot M, Messas E. Myocardial Stiffness Evaluation Using Noninvasive Shear Wave Imaging in Healthy and Hypertrophic Cardiomyopathic Adults. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1135-1145.
Zores F, Iliou M-C, Gellen B, Kubas S, Berthelot E, Guillo P, Bauer F, Lamblin N, Bosser G, Damy T, Cohen-Solal A, Beauvais F. Physical activity for patients with heart failure: Position paper from the heart failure (GICC) and cardiac rehabilitation (GERS-P) Working Groups of the French Society of Cardiology. Arch Cardiovasc Dis. 2019;112(11):723-731.

2018

Audureau E, Guellich A, Guery E, Canoui-Poitrine F, Benedyga V, Duchossoir H, Taieb C, Damy T. Development and Validation of a New Tool to Assess Burden of Dietary Sodium Restriction in Patients with Chronic Heart Failure: The BIRD Questionnaire. Nutrients. 2018;10(10).
Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, Audureau E, Bodez D, Rahmouni A, Deux J-F. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018;20(1):58.
Berthelot E, Bauer F, Eicher J-C, Flécher E, Gellen B, Guihaire J, Guijarro D, Roul G, Salvat M, Tribouilloy C, Zores F, Lamblin N, De Groote P, Damy T. Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues. ESC Heart Fail. 2018;5(5):755-763.
McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, Cohen-Solal A, Kindermann I, Manito N, Pfister O, Pohjantähti-Maaroos H, Taylor J, Comin-Colet J. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664-1672.
Abulizi M, Cottereau A-S, Guellich A, Vandeventer S, Galat A, Van Der Gucht A, Planté-Bordeneuve V, Dubois-Randé J-L, Bodez D, Rosso J, Damy T, Itti E. Early-phase myocardial uptake intensity of Tc-HMDP vs Tc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis. J Nucl Cardiol. 2018;25(1):217-222.
Cantrelle C, Dorent R, Legeai C, Damy T, Bastien O, Tuppin P. Hospitalisation and life support in the year before and during heart transplantation: a French national study. Open Heart. 2018;5(2):e000913.
Chevance V, Damy T, Tacher V, Legou F, Ridouani F, Luciani A, Kobeiter H, Rahmouni A, Deux J-F. Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study. Eur Radiol. 2018;28(2):816-823.
d'Humières T, Fard D, Damy T, Roubille F, Galat A, Doan H-L, Oliver L, Dubois-Randé J-L, Squara P, Lim P, Ternacle J. Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Arch Cardiovasc Dis. 2018;111(10):582-590.
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806.
Lefaucheur J-P, Zouari HG, Gorram F, Nordine T, Damy T, Planté-Bordeneuve V. The value of electrochemical skin conductance measurement using Sudoscan® in the assessment of patients with familial amyloid polyneuropathy. Clin Neurophysiol. 2018;129(8):1565-1569.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.
Mohty D, Petitalot V, Magne J, Fadel BM, Boulogne C, Rouabhia D, Hamel CEl, Lavergne D, Damy T, Aboyans V, Jaccard A. Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study. J Cardiol. 2018;71(4):419-427.
Van Der Gucht A, Cottereau A-S, Abulizi M, Guellich A, Blanc-Durand P, Israël J-M, Galat A, Planté-Bordeneuve V, Dubois-Randé J-L, Bodez D, Rosso J, Damy T, Itti E. Apical sparing pattern of left ventricular myocardial Tc-HMDP uptake in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018;25(6):2072-2079.
Mohty D, Petitalot V, Magne J, Fadel BM, Boulogne C, Rouabhia D, Hamel CEl, Lavergne D, Damy T, Aboyans V, Jaccard A. Author's reply. J Cardiol. 2018;72(4):368.

2017

Béquignon E, Guellich A, Bartier S, Raynal M, Prulière-Escabasse V, Canoui-Poitrine F, Coste A, Damy T. How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss inelderly-AmyloDEAFNESS pilot study. Amyloid. 2017;24(2):96-100.

2016

Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil J-P, Benhaiem N, Hittinger L, Dubois-Randé J-L, Planté-Bordeneuve V, Mohty D, Deux J-F, Damy T. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2016;9(2):126-38.
Nielsen L, Canoui-Poitrine F, Jais J-P, Dahmane D, Bartolucci P, Bentaarit B, Gellen-Dautremer J, Remy P, Kofman T, Matignon M, Suberbielle C, Jacquelinet C, Wagner-Ballon O, Sahali D, Lang P, Damy T, Galactéros F, Grimbert P, Habibi A, Audard V. Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients. Br J Haematol. 2016;174(1):148-52.
Gellen B, Canoui-Poitrine F, Boyer L, Drouot X, Le Thuaut A, Bodez D, Covali-Noroc A, D'ortho MPia, Guendouz S, Rappeneau S, Kharoubi M, Dubois-Randé J-L, Hittinger L, Adnot S, Bastuji-Garin S, Damy T. Apnea-hypopnea and desaturations in heart failure with reduced ejection fraction: Are we aiming at the right target?. Int J Cardiol. 2016;203:1022-8.
Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DMessika, Milleron O, Attias D, Dubois-Randé J-L, Mohty D, Audureau E, Teiger E, Rosso J, Monin J-L, Damy T. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?. Eur Heart J. 2016;37(47):3525-3531.
Damy T, Costes B, Hagège AA, Donal E, Eicher J-C, Slama M, Guellich A, Rappeneau S, Gueffet J-P, Logeart D, Planté-Bordeneuve V, Bouvaist H, Huttin O, Mulak G, Dubois-Randé J-L, Goossens M, Canoui-Poitrine F, Buxbaum JN. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826-34.
Boyer L, Audureau E, Margarit L, Marcos E, Bizard E, Le Corvoisier P, Macquin-Mavier I, Derumeaux G, Damy T, Drouot X, Covali-Noroc A, Boczkowski J, Bastuji-Garin S, Adnot S. Telomere Shortening in Middle-Aged Men with Sleep-disordered Breathing. Ann Am Thorac Soc. 2016;13(7):1136-43.

2015

Parisot J, Damy T, Gellen B, Covali-Noroc A, Bodez D, Rappeneau S, Guellich A, Adnot S, Bastuji-Garin S, Hittinger L, d'Ortho M-P, Boyer L, Canoui-Poitrine F. Sleep-disordered breathing in chronic heart failure: development and validation of a clinical screening score. Sleep Med. 2015;16(9):1094-101.

2013

Gellen B, Canoui-Poitrine F, Lesault P-F, Le Thuaut A, Lim P, Gueret P, Guendouz S, Pongas D, Teiger E, Dubois-Randé J-L, Hittinger L, Damy T. Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure. Am J Cardiol. 2013;112(10):1619-24.